JPH052652B2 - - Google Patents
Info
- Publication number
- JPH052652B2 JPH052652B2 JP4490284A JP4490284A JPH052652B2 JP H052652 B2 JPH052652 B2 JP H052652B2 JP 4490284 A JP4490284 A JP 4490284A JP 4490284 A JP4490284 A JP 4490284A JP H052652 B2 JPH052652 B2 JP H052652B2
- Authority
- JP
- Japan
- Prior art keywords
- dextran
- intrinsic viscosity
- lipid
- lowering
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920002307 Dextran Polymers 0.000 claims description 71
- 239000003524 antilipemic agent Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 229960004793 sucrose Drugs 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 229930006000 Sucrose Natural products 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241001468194 Leuconostoc mesenteroides subsp. dextranicum Species 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- -1 carboxymethylstarch Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Description
æ¬çºæã¯ãããªã°ãªã»ã©ã€ãïŒäžæ§èèªïŒãã³
ã¬ã¹ãããŒã«ã®åŠãè質ã®äœäžïŒäœäžä¹è³å¢å æ
å¶ïŒã«æçšãªè質äœäžå€ã«é¢ãããšãã«ãé·ææ
äžã«ããå¯äœçšããªããäžã€å倧éæäžã«ããäž
ç¢ãè
¹çãªã©ã®å¯äœçšã䌎ããããã®ãªãäœæäž
éã§åè¶ããè¡äžè質äœäžå¹æãçºæ®ã§ããæŽã«
èè質äœäžå¹æãã瀺ãè質äœäžå€ã«é¢ããã
æŽã«è©³ããã¯ãæ¬çºæã¯æ¥µéç²åºŠïŒ»Î·ïŒœã0.29
ã1.1ã®éšåå解ããã¹ãã©ã³ãæå¹æåãšããŠ
å«æããããšãç¹åŸŽãšããè質äœäžå€ã«é¢ããã
è¿å¹Žãæ人ç
ãšããŠåé¡ã«ãªã€ãŠããäŸãã°å
è硬åçãšé¢ä¿ããéèŠãªå åã®äžã€ãšããŠãè¡
液äžã®è質ã®å¢å ã«ããé«èè¡çã泚ç®ãããè¡
äžè質ã®äœäžã®å¿
èŠæ§ãèªèãããŠããã
æè¿ãã®ãããªè質ã®äœäžã«å€ãã®é£ç©ç¹ç¶ã
å©çšãããç¹ã«ãã¯ãã³ãã°ã«ã³ãã³ãã³ãã°ã¢
ã¬ã ãªã©ã®æ°Žæº¶æ§é£ç©ç¹ç¶ã§ãã®äœçšã匷ãçŸã
ããããšãç¥ãããŠããããããããããã®é£ç©
ç¹ç¶ã®æå¹éã¯äžè¬ã«åç©å®éšã§10ã30gïŒKgâ
äœéïŒæ¥ãèšåºå¿çšã®å Žåã§ã50ã500mgïŒKgâ
äœéïŒæ¥ãšæ¥µããŠå€éã§ããããã®çµæãåæ°ã
äžç¢ãè
¹çãªã©ã®å¯äœçšãã¿ãããããšã®ã»ãã
ãã¿ãã³ãããã©ã«ãªã©ã®æ¬ ä¹çãšãªãå±éºæ§ã®
æããããããããããé£ç©ç¹ç¶ã¯å¿
ããããæº
足ãã¹ãè質äœäžå€ãšã¯èšãé£ãçŸç¶ã«ããã
åŸæ¥ãããã¹ãã©ã³ãå
å«ããé£æ¶åæ§å€ç³
é¡ããªãªãŽç³é¡åã³ãããã®èªå°äœãããªã矀ã
ãããã°ããç³é¡ãæå¹æåãšããŠå«æããããš
ãç¹åŸŽãšããè¡ç³äœäžå€ã®ææ¡ïŒç¹éæ57â
146713å·ïŒãç¥ãããŠããããããŠããã®ææ¡ã«
ã¯ãã€ããã»ããã¹ãã©ã³ïŒnative dextranïŒã®
ã»ãã«ããã®éšåå解ããã¹ãã©ã³ã®äœ¿çšã«ã€ã
ãŠãé瀺ãããååé60000ïŒæ¥µéç²åºŠãηãçŽ
0.22ã«çžåœããïŒã90000ïŒæ¥µéç²åºŠãηãçŽ
0.275ã«çžåœããïŒã®ããã¹ãã©ã³ãè¡ç³äœäžå¹
æã瀺ããããšãé瀺ãããŠããã
ããããªããã該ç¹éæ57â146713å·ææ¡ã«
ã¯ãååé60000ã90000ã®ããã¹ãã©ã³ä»¥å€ã®å
åéã®éšåå解ããã¹ãã©ã³ã®è¡ç³äœäžå¹æã«é¢
ããŠã¯èšåãããŠããªãããäžã€åãè¡æ¶²äžã®ã
ãªã°ãªã»ã©ã€ããã³ã¬ã¹ãããŒã«ã®åŠãè質ã«å¯Ÿ
ããããã¹ãã©ã³ã®äœçšã«é¢ããŠã¯å
šãèšåãã
ãŠããªããåŸã€ãŠãŸããåœç¶ã®ããšãªãããè質
ã«å¯Ÿããããã¹ãã©ã³ã®äœçšãšè©²ããã¹ãã©ã³ã®
ååéãããã¯æ¥µéç²åºŠãšã®é¢ä¿ã«ã€ããŠã®åŠäœ
ãªãç¥èŠã瀺åãé瀺ãããŠããªãã
æŽã«ãNew Food IndustryïŒVol.25ïŒNo.ïŒ
ïŒ1983ïŒïŒ13ã15é ã«ããããã¹ãã©ã³ãå
å«ãã
αâïŒïŒïŒçµåã®å€ç³é¡ã«ã€ããŠãâè¡ç³å€äžæ
å¶åŸ¡ç©è³ªãæ·»å ããç ç³ã®éçºãããã€ãŠâãšé¡
ããŠå ±åãããŠããããã®æç®ã«ã¯ãååéçŽ
70000ïŒæ¥µéç²åºŠãηãçŽ0.23ã«çžåœããïŒã®ãã
ã¹ãã©ã³ãç ç³ã«æ·»å ããŠã©ããã«æäžãããšè¡
ç³ã®äžæãæå¶ãããããšããã³è©²ããã¹ãã©ã³
ã®ç ç³ã«å¯Ÿããææå¹æ·»å éã¯1/1000ã§ããããš
ãèšèŒãããŠããã
ããããªããããã®æç®ã«ããäžèšååé以å€
ã®ååéã®éšåå解ããã¹ãã©ã³ã«é¢ããŠã¯èšå
ãããŠããªãããäžã€åãè¡æ¶²äžã®è質ã«å¯Ÿãã
ããã¹ãã©ã³ã®äœçšãæŽã«ã¯ãããã¹ãã©ã³ã®è
質ã«å¯Ÿããäœçšãšè©²ããã¹ãã©ã³ã®ååéããã
ã¯æ¥µéç²åºŠãšã®é¢ä¿ã«ã€ããŠãªã©ãå
šç¶ãèšåã
ããŠããªãã瀺åããªãããŠããªãã
äžæ¹ãç±³åœç¹èš±3148114å·æ现æžïŒ1964幎ïŒæ
ïŒæ¥åè¡ïŒã«ã¯ãè¡äžã³ã¬ã¹ãããŒã«ã®äœäžæ¹æ³
ã«é¢ããŠé瀺ãããŠããããã®ææ¡ã«ã¯ãè¡äžã³
ã¬ã¹ãããŒã«äœäžäœçšã瀺ãç²æ¶²è³ªç©è³ª
ïŒmucilaginous substancesïŒãšããŠãååŠçã«
èãããç°ãªã€ãå€æ°ã®ç²æ¶²è³ªç©è³ªãçŸ
åãããŠ
ããããããç²æ¶²è³ªç©è³ªã®äžäŸãšããŠã·ãŠãŒã¯ã
ãŒã¹ã®åŸ®çç©ã«ããäœçšã§çç£ãããããã¹ãã©
ã³ãäŸç€ºãããŠããã
ããããªããããã®ææ¡ã«ãããŠã¯ã䜿çšãã
ããã¹ãã©ã³ã®ååéãããã¯æ¥µéç²åºŠãηãã«
ã€ããŠã¯ãå
šç¶ãèšåãããŠããªãããäŸãã°ã
ã·ãšç³ã®Leuconostoc dextranicumã«ããäœçš
ã§çç£ãããããã¹ãã©ã³ã®åŠããã€ããã»ãã
ã¹ãã©ã³ïŒnative dextranïŒãäŸç€ºãããŠããã
éåžžLeuconostoc dextranicumãLeuconostoc
mecenteroidsã®äœçšã§åŸããããã€ããã»ãã
ã¹ãã©ã³ã¯ååéãçŽ400äžãçŽ1000äžã®ãªãŒã
ãŒãšããããŠããã
æŽã«ããã®ææ¡ã«ã¯ãç²æ¶²è³ªç©è³ªã®æäžéãšã
ãŠ50ã500mgïŒKgâäœéïŒæ¥ã®æäžéãäŸç€ºãã
ãŠãããåãïŒã30gïŒKgâé£ç©ã®ç¯å²éã§ã®ç²
液質ç©è³ªã®é£ç©ãžã®æ·»å ã«ãã€ãŠãè¡äžã³ã¬ã¹ã
ããŒã«ã®æ倧ã®äœäžãå©é·ããããšèšèŒãããŠã
ãããäžèšäŸç€ºéã®åŠãéã§ã®ãã€ããã»ããã¹
ãã©ã³æäžã«ã¯äžç¢ãè
¹çãªã©ã®å¯äœçšã䌎ãæ
ããããã
åæŽã«ããã®ææ¡ã«ã¯ãããªã°ãªã»ã©ã€ãã«å¯Ÿ
ããããã¹ãã©ã³ããã³ãã®ä»ã®ç²æ¶²è³ªç©è³ªã®äœ
çšã«ã€ããŠã¯å
šãèšåãããŠããªãã
ãããŠããã®ææ¡ã«ãããŠããæ¬çºæã«ãããŠ
ç¹å®ããã極éç²åºŠãηãã®éšåå解ããã¹ãã©
ã³ã«ã€ããŠã¯ãå
šç¶ãèšåãããŠããªãããåŸã€
ãŠãŸããåœç¶ã®ããšãªãããè質ã«å¯Ÿããéšåå
解ããã¹ãã©ã³ã®äœçšãšè©²ããã¹ãã©ã³ã®ååé
ãããã¯æ¥µéç²åºŠãšã®é¢ä¿ã«ã€ããŠã®åŠäœãªãç¥
èŠã瀺åãé瀺ãããŠããªãã
æ¬çºæè
çã¯ãæ¯æ§ã®ç¹ã§å®å
šãªããã¹ãã©ã³
ãå©çšããŠãé·ææäžãæäžéã«ããå¯äœçšã®ãª
ãè質äœäžå€ãéçºãã¹ãç 究ãè¡ã€ãŠããã
ãã®çµæãè質ã«å¯Ÿããããã¹ãã©ã³ã®äœçšãš
該ããã¹ãã©ã³ã®æ¥µéç²åºŠãηããšã®éã«ã¯å¯æ¥
ãªçžé¢é¢ä¿ãååšããããšãçºèŠããããã®çºèŠ
ã«åºããŠæŽã«ç 究ãé²ããçµæãç¹å®ç¯å²ã®æ¥µé
ç²åºŠãηããæããéšåå解ããã¹ãã©ã³ã¯ãé·
ææäžãæäžéã«ããå¯äœçšãçããããšãªã
ã«ãäœæäžéã§ãè¡äžããªã°ãªã»ãªãåã³ã³ã¬ã¹
ãããŒã«ã®äœäžä¹è³å¢å æå¶ã«é¡èã«åªããå¹æ
ãçºæ®ããããšãçºèŠããã
æ¬çºæè
çã®ç 究ã«ããã°ãåè¿°ãããããªåŸ
æ¥ææ¡ã«ãããããã¹ãã©ã³ã®æ¥µéç²åºŠãηãé
åãšã¯ç°ãªã€ã極éç²åºŠãηãã0.29ã1.1ã®é
åã«å±ããéšåå解ããã¹ãã©ã³ã¯ãäŸãã°ïŒã
40mgïŒKgâäœéïŒæ¥ã奜ãŸããã¯ïŒã30mgïŒKgâ
äœéïŒæ¥ã®äœæäžéã§çµå£æäžãããšãè¡æ¶²äžã®
ããªã°ãªã»ã©ã€ãåã³ã³ã¬ã¹ãããŒã«ã®äœäžä¹è³
å¢å æå¶ã«ãé¡èã«åªããå¹æã瀺ãäžã€é·ææ
äžã«ãã€ãŠãå¯äœçšãçãããããããªããæŽ
ã«ãèè質ã®äœäžã«ãåªããå¹æãçºæ®ãããŠã
ãŒã¯ãªè質äœäžå€ã§ããããšãçºèŠããã
åŸã€ãŠãæ¬çºæã®ç®çã¯åªããè質äœäžå€ãæ
äŸããã«ããã
æ¬çºæã®äžèšç®çåã³æŽã«å€ãã®ä»ã®ç®çãªã
ã³ã«å©ç¹ã¯ã以äžã®èšèŒããäžå±€æãããšãªãã§
ãããã
æ¬çºæã®è質äœäžå€ã¯ã極éç²åºŠãηãã0.29
ã1.1ã®éšåå解ããã¹ãã©ã³ãæå¹æåãšããŠ
å«æããããã®ãããªéšåå解ããã¹ãã©ã³ãã
èªäœã¯ç¥ãããŠãããäŸãã°ãLeuconostoc
mecenteroidsïŒLeuconostoc dextranicumãªã©
ã®åŠãå
¬ç¥strainãå©çšããŠãããèªäœå
¬ç¥ã®æ
æ³ã«ãããã·ãšç³ããçæããããã€ããã»ãã
ã¹ãã©ã³ããããèªäœå
¬ç¥ã®ææ³ã«ããéšå氎解
åŠçããŠåŸãããšãã§ããããåãåžå Žã§å
¥æã
ãããšãã§ããã
æ¬çºæã«ãããŠã¯ããã®ãããªéšåå解ããã¹
ãã©ã³ã§ãã€ãŠã極éç²åºŠãηãã0.29ã1.1ïŒå
åéçŽ10äžãçŽ150äžã«çžåœããïŒã®éšåå解ã
ãã¹ãã©ã³ãéžæããŠå©çšããããã®ãããªéšå
å解ããã¹ãã©ã³ã®æ¯æ§ïŒLD50ïŒã¯ãçµå£æäž
ïŒããŠã¹ïŒã§10gïŒKg以äžãšæ¥µããŠäœæ¯æ§ã§ãã€
ãŠãå®å
šã«å©çšããããšãã§ããã
å°ãæ¬çºæã«æŒãŠãéšåå解ããã¹ãã©ã³ã®æ¥µ
éç²åºŠãηãã¯ãäžèšã«ãã枬å®ç®åºãããã
極éç²åºŠãηãã®æž¬å®ç®åºïŒâ
0.05ã0.2gã®ããã¹ãã©ã³ãæ°Žã«æº¶ãããæ£ç¢º
ã«100mlãšããè©Šæ溶液ãšããããŠãããŒãåç²
床èšãçšããŠã該詊æ溶液åã³äœ¿çšããæ°Žã®ãã
ããã«ã€ããŠ25â±0.02âã«ãããæµäžæéã枬
å®ããäžèšåŒã«ãã€ãŠæ¥µéç²åºŠãηããç®åºæ±ºå®
ããã
極éç²åºŠãηãïŒlnè©Šæ溶液ã®æµäžæé
ïŒç§ïŒïŒæ°Žã®æµäžæéïŒç§ïŒïŒè©Šæã®éïŒïœïŒ
ãªããäžèšæ¥µéç²åºŠããè©Šæããã¹ãã©ã³ã®é
éå¹³åååéïŒïŒïœïŒã¯äžèšåŒã«ãã€ãŠæ±ããã
ãšãã§ããã
ãηãïŒ9.00Ã104 ïŒw0.50
æ¬çºæã®æ¥µéç²åºŠãηãã0.29ã1.1ã奜ãŸã
ãã¯0.3ã1.06ã®éšåå解ããã¹ãã©ã³ãæå¹æ
åãšããè質äœäžå€ã¯ãäœæäžéã§ããªã°ãªã»ã©
ã€ãåã³ã³ã¬ã¹ãããŒã«ã«å¯ŸããŠãèªãåŸãäœç
ã®å¯äœçšã䌎ãããšãªãã«ãåªããäœäžå¹æãçº
æ®ããããšãã§ããã該æäžéãšããŠã¯ã該æå¹
æåéãšããŠãïŒã40mgïŒKgâäœéïŒæ¥ã奜ãŸã
ãã¯ïŒã30mgïŒKgâäœéïŒæ¥ã®äœæäžéïŒçµå£æ
äžïŒãäŸç€ºããããšãã§ãããæŽã«ãæ¬çºææå¹
æåã¯ãè¡äžã®ã³ã¬ã¹ãããŒã«ã®ä»ã«ããªã°ãªã»
ã©ã€ãã«å¯ŸããŠãåªããäœäžå¹æã瀺ãã®ã«å ã
ãŠãèè質ã®äœäžã«å¯ŸããŠã泚ç®ãã¹ãäœäžå¹æ
ã瀺ããæ¬çºæè
çã®æ€èšã«ããã°ããã€ããã»
ããã¹ãã©ã³ïŒååéçŽ400äžãçŽ1000äžã®ãªãŒ
ããŒïŒã¯ããªã°ãªã»ã©ã€ãã«å¯ŸããŠå®çšæ§ããäœ
äžå¹æãäœæäžéã§çºæ®ããªãããæäžéãå¢ã
ãšäžç¢ãè
¹çãªã©ã®äžéœåãªå¯äœçšãçŸãããæ
ããããããæ¬çºææå¹æåã¯ãåè¿°ã®åŠãäœæ
äžéã§è¡äžããªã°ãªã»ã©ã€ãåã³ã³ã¬ã¹ãããŒã«
ã«å¯ŸããŠåªããäœäžå¹æãçºæ®ããæŽã«ãèè質
ã«å¯ŸããŠãåªããäœäžå¹æã瀺ããå ããŠãäœç
å¯äœçšã䌎ããªãå©ç¹ãæããã
æ¬çºæã®è質äœäžå€ã¯ãä»»æã®çµå£æäžå€åã§
ããããšãã§ããäŸãã°ãè»ã«ãã»ã«å€ïŒsoft
capsulaeïŒã硬ã«ãã»ã«å€ïŒhard capsulaeïŒãé¡
ç²å€ïŒgranulaïŒãäžžå€ïŒpilulaeïŒãæ£å€
ïŒpulvecesïŒãé å€ïŒtabellaeïŒãã·ãããå€
ïŒsyrupiïŒããããŒãå€ïŒtrochisiïŒããšãªãã·ã«å€
ïŒelixiriaïŒãªã©ã®åŠãå€åãäŸç€ºããããšãã§ã
ãããã®ãããªå€åãžã®èª¿è£œæ段ã¯åœæ¥è
ã«ãã
ç¥ãããŠãããæ¬çºæã§å©çšã§ããã
æ¬çºæã®è質äœäžå€ã¯ã極éç²åºŠãηãã0.29
ã1.1ã®éšåå解ããã¹ãã©ã³ãæå¹æåãšããŠ
å«æããã»ãã«ãè¬åŠçã«èš±å®¹ãåŸãçšéå€ä¹è³
æ
äœãæŽã«å«æããçµæç©ã®åœ¢æ
ã§ããããšãã§
ããããã®ãããªåœ¢æ
ã«ãããŠã該æå¹æåã®å«
æéã¯é©åœã«éžæããããšãã§ããã該å«æéã¯
å€åã«ãã€ãŠãé©åœã«éžæå€æŽã§ããããäŸãã°
çµæç©ééã«åºããŠãçŽïŒãçŽ99ééïŒ
ã奜ãŸã
ãã¯çŽïŒãçŽ95ééïŒ
ã®åŠãå«æéãäŸç€ºããã
ãšãã§ããã
ãã®ãããªçµæç©ã«å©çšããçšéå€ä¹è³æ
äœã®
äŸãšããŠã¯ãã«ã©ã€ãŽã ãã¢ã©ãã¢ãŽã ããã©ã¬
ã³ããã°ã¢ã¬ã ãã«ã©ã®ãã³ãã¢ã«ã®ã³é
žãããª
ãŠã ãã«ãŒã€ã³ããŒã©ãã³ãã°ã«ãã³ããã¬ã€ã·
ãšã§ãã·ããã³ã ã®ã§ãã·ããããŠã¢ãã³ã·ã§ã
ã·ããç±³ã§ãã·ãããµããã€ã¢ã§ãã·ããå¯å€©ã
ã»ã©ãã¯ãã°ã«ã³ãã³ãã³ãããªããã«ãããªã
ã³ãããªããã«ã¢ã«ã³ãŒã«ãããªããã«ã¢ã»ããŒ
ããããªãšãã¬ã³ã°ãªã³ãŒã«ãã¡ãã«ã»ã«ããŒ
ã¹ããšãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ã
ãŒã¹ãããããã·ãšãã«ã»ã«ããŒã¹ãããããã·
ãããã«ã»ã«ããŒã¹ãããããã·ãããã«ã¹ã¿ãŒ
ããã«ã«ããã·ã¡ãã«ã¹ã¿ãŒããé
¢é
žãã¿ã«é
žã»
ã«ããŒã¹ãããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹
ãã¿ã¬ãŒããçé
žæ°ŽçŽ ãããªãŠã ãé
žåãã°ãã·
ãŠã ãä¹³é
žã«ã«ã·ãŠã ãçé
žã«ã«ã·ãŠã ããªã³é
ž
ã«ã«ã·ãŠã ãåæã±ã€é
žã¢ã«ãããŠã ãã¹ãã¢ãª
ã³é
žãã°ãã·ãŠã ãã¡ã¿ã±ã€é
žã¢ã«ãã³é
žãã°ã
ã·ãŠã ãã±ã€é
žãã¿ã«ã¯ãããŠé
žãç¡«é
žã«ã«ã·ãŠ
ã ãå®æ¯éŠé
žãã¯ãšã³é
žãã³ãã¯é
žãé
ç³é
žãã°
ã«ã³ã³é
žãã°ãªã»ãªã³ãã·ãšç³ããã³ãããŒã«ã
ãããŠç³ããœã«ãããŒã«ãä¹³ç³ãæç³ããµãã«ãª
ã³ãæ°Žããšã¿ããŒã«ããªã©ãäŸç€ºããããšãã§ã
ãã
æ¬çºæã®è質äœäžå€ã¯ãé«èè¡çãããã¯ãã®
ãããã®ãã人éã«å¯ŸããŠãåèšã®éã§çµå£æäž
ããããšãã§ããã
é«èè¡çãšããŠã¯å®¶ææ§ãããã¯ç¹çºæ§ã«ãã
ãäžæ¬¡æ§ã®ãã®ã§ãäŸãã°å åè硬åçïŒèè¡æ§
å¿çŸæ£ãå¿çæ¢å¡ïŒãè³åè硬åçïŒè³æ¢å¡ãè³
è¡æ ïŒãªã©ã®åè硬åçåã³èèªèãªã©ã®åå ãš
ãªããã®ã§ãã€ãŠãããããŸããè¥æºçãç³å°¿
ç
ãç³ä»£è¬ç°åžžçãé«ã€ã³ã¹ãªã³è¡çãªã©ã«ãã
èªçºãããäºæ¬¡æ§ã®é«èè¡çã§ãã€ãŠããããæŽ
ã«ãäºæ¬¡æ§ã®é«èè¡çãèªçºããæãã®ããäžèš
åçŸæ£åã³é«èè¡çã®æãã®ãã人éïŒå¥åžžäººã
å
å«ããïŒã«å¯ŸããŠäºé²ã®ããã«æ¬çºæã®éšåå
解ããã¹ãã©ã³ãæäžããããšãã§ããã
次ã«ããã¹ãã©ã³ã®è質äœäžå¹æã«ã€ããŠç€º
ãã
è©ŠéšäŸ ïŒ
äœé105gååŸã®ãŠã€ã¹ã¿ãŒïŒWistarïŒç³»éæ§
ã©ããã«ã極éç²åºŠãηãã0.11ã1.72ã®ããã¹
ãã©ã³ãããããé
åããé«ã·ãšç³é£ïŒé«ã·ãšç³
é£å¯Ÿããã¹ãã©ã³ïŒ500察ïŒïŒãèªç±æåãããŠã
14æ¥é飌è²ããåŸãåžžæ³ã«ãããè¡æž
ããªã°ãªã»
ã©ã€ãïŒTGïŒãè¡æž
ç·ã³ã¬ã¹ãããŒã«ïŒTCïŒå
ã³è¡ç³ãå®éããã
çµæã第ïŒè¡šã«ç€ºãã
The present invention relates to a lipid-lowering agent that is useful for lowering (reducing or inhibiting increase in) lipids such as triglycerides (neutral fats) and cholesterol, and in particular, does not cause side effects when administered for a long period of time, and does not cause diarrhea, abdominal pain, etc. when administered in large doses. The present invention relates to a lipid-lowering agent that can exhibit an outstanding blood lipid-lowering effect at a low dosage without causing side effects, and also exhibits a hepatic lipid-lowering effect. More specifically, the present invention has an intrinsic viscosity [η] of 0.29.
The present invention relates to a lipid-lowering agent characterized by containing a partially degraded dextran of ~1.1 as an active ingredient. In recent years, hyperlipidemia due to an increase in blood lipids has attracted attention as one of the important factors related to arteriosclerosis, which has become a problem as an adult disease, and the need to lower blood lipids has been recognized. has been done. Recently, many dietary fibers have been used to lower lipid levels, and it is known that this effect is particularly strong with water-soluble dietary fibers such as pectin, glucomannan, and guar gum. However, the effective amount of these dietary fibers is generally 10 to 30 g/Kg in animal experiments.
Body weight/day, 50-500mg/Kg- even in clinical applications
body weight per day, resulting in nausea,
In addition to side effects such as diarrhea and abdominal pain,
At present, these dietary fibers cannot necessarily be said to be satisfactory lipid-lowering agents because of the risk of vitamin and mineral deficiencies. Hitherto, a proposal has been made for a hypoglycemic agent characterized by containing as an active ingredient a saccharide selected from the group consisting of indigestible polysaccharides, oligosaccharides, and derivatives thereof, including dextran (Japanese Patent Application Laid-Open No. 1983-1999).
No. 146713) is known. In addition to native dextran, this proposal also discloses the use of partially decomposed dextran, with a molecular weight of 60,000 (intrinsic viscosity [η] approximately
0.22) ~ 90000 (intrinsic viscosity [η] approx.
It has been disclosed that dextran (equivalent to 0.275) showed hypoglycemic effects. However, the proposal in JP-A-57-146713 does not mention the blood sugar-lowering effect of partially decomposed dextrans with molecular weights other than dextrans with molecular weights of 60,000 to 90,000, and also does not mention the effect of lowering blood sugar levels on lipids such as triglycerides and cholesterol in the blood. There is no mention of the effect of dextran on. Therefore, as a matter of course, no knowledge or suggestion is disclosed regarding the relationship between the effect of dextran on lipids and the molecular weight or intrinsic viscosity of the dextran. Furthermore, New Food Industry, Vol.25, No.3
(1983), pp. 13-15, also reports on α-1,6-linked polysaccharides including dextran under the title ``Development of sugars containing substances that control blood sugar levels''. This literature states that the molecular weight of approx.
70,000 (corresponding to an intrinsic viscosity [η] of approximately 0.23) added to sugar and administered to rats suppresses the rise in blood sugar, and the most effective amount of dextran to be added to sugar is 1/1000. is listed. However, this document does not mention partially decomposed dextran with a molecular weight other than the above-mentioned molecular weight, and furthermore, the effect of dextran on lipids in the blood, the effect of dextran on lipids, and the molecular weight or limit of the dextran. There is no mention or suggestion of any relationship with viscosity. On the other hand, US Pat. No. 3,148,114 (published September 8, 1964) discloses a method for lowering blood cholesterol. This proposal lists a large number of mucilaginous substances that are chemically significantly different as mucilaginous substances that exhibit blood cholesterol-lowering effects. The dextran produced is illustrated. However, in this proposal, there is no mention of the molecular weight or intrinsic viscosity [η] of the dextran used, but for example,
Native dextran such as dextran produced by the action of sucrose by Leuconostoc dextranicum is exemplified.
Usually Leuconostoc dextranicum or Leuconostoc
Native dextran obtained by the action of mecenteroids is said to have a molecular weight on the order of about 4 million to about 10 million. Furthermore, this proposal exemplifies the dosage of mucilaginous substances in doses ranging from 50 to 500 mg/Kg - body weight/day, and also the administration of mucilaginous substances to food in amounts ranging from 5 to 30 g/Kg - food. Although it is stated that the addition of native dextran promotes the maximum reduction in blood cholesterol, administration of native dextran in amounts such as those exemplified above may be accompanied by side effects such as diarrhea and abdominal pain. Furthermore, this proposal makes no mention of the effect of dextran and other mucilaginous substances on triglycerides. Also, in this proposal, there is no mention at all of the partially decomposed dextran with the intrinsic viscosity [η] specified in the present invention. No knowledge or suggestion regarding the relationship between the molecular weight or intrinsic viscosity of dextran is disclosed. The present inventors have conducted research to develop a lipid-lowering agent that does not have side effects due to long-term administration or dosage by using dextran, which is safe in terms of toxicity. As a result, it was discovered that there is a close correlation between the action of dextran on lipids and the intrinsic viscosity [η] of the dextran. Further research based on this discovery revealed that partially degraded dextran with a specific range of intrinsic viscosity [η] can reduce blood triglycerides and cholesterol levels at low doses without causing long-term administration or dose-related side effects. It has been discovered that it exhibits a remarkable effect in suppressing the decrease or increase in . According to the research conducted by the present inventors, partially decomposed dextrans which belong to a region with an intrinsic viscosity [η] of 0.29 to 1.1, which is different from the region of intrinsic viscosity [η] of dextran proposed in the prior art as described above, have a
40mg/Kg-body weight/day, preferably 4-30mg/Kg-
When administered orally at a low dose per body weight per day, it shows a remarkable effect on lowering or suppressing the increase in triglycerides and cholesterol in the blood, and there is no risk of side effects even with long-term administration. The researchers discovered that it is a unique lipid-lowering agent that is also highly effective in lowering blood pressure. Therefore, an object of the present invention is to provide an excellent lipid-lowering agent. The above objects and many other objects and advantages of the present invention will become more apparent from the following description. The lipid-lowering agent of the present invention has an intrinsic viscosity [η] of 0.29.
Contains ~1.1 partially degraded dextran as an active ingredient. Such partially degraded dextrans are known per se, for example Leuconostoc
Native dextran produced from sucrose can be obtained by partial hydrolysis using known strains such as mecenteroids, Leuconostoc dextranicum, etc., by a method known per se. , also available on the market. In the present invention, a partially decomposed dextran having an intrinsic viscosity [η] of 0.29 to 1.1 (corresponding to a molecular weight of about 100,000 to about 1,500,000) is selected and used. The toxicity (LD 50 ) of such partially degraded dextran is extremely low at 10 g/Kg or more when administered orally (in mice), and it can be used safely. In the present invention, the intrinsic viscosity [η] of partially decomposed dextran is measured and calculated as follows. Measurement and calculation of intrinsic viscosity [η]: - Dissolve 0.05 to 0.2 g of dextran in water to make exactly 100 ml and use it as the sample solution. Using an Ubbelohde viscometer, measure the flow time at 25°C ± 0.02°C for each of the sample solution and the water used, and calculate and determine the limiting viscosity [η] using the following formula. Intrinsic viscosity [η] = ln Sample solution flow time (seconds) / Water flow time (seconds) / Sample amount (g) From the above intrinsic viscosity, the weight average molecular weight ( M w) of the sample dextran can be calculated using the above formula. You can ask for it. [η] = 9.00Ã10 4 M w 0.50 The lipid-lowering agent of the present invention containing partially decomposed dextran having an intrinsic viscosity [η] of 0.29 to 1.1, preferably 0.3 to 1.06 as an active ingredient can reduce triglyceride and cholesterol at low doses. It is possible to exhibit an excellent lowering effect on , without any observable side effects. Examples of the dosage include a low dosage (oral administration) of 3 to 40 mg/Kg body weight/day, preferably 4 to 30 mg/Kg body weight/day of the active ingredient. Furthermore, the active ingredient of the present invention not only exhibits an excellent lowering effect on not only blood cholesterol but also triglycerides, it also exhibits a remarkable lowering effect on hepatic lipids. According to the study by the present inventors, native
Dextran (molecular weight on the order of about 4 million to about 10 million) does not have a practical lowering effect on triglycerides at low doses, and when the dose is increased, there is a risk of untoward side effects such as diarrhea and abdominal pain. However, the active ingredient of the present invention exhibits an excellent lowering effect on blood triglycerides and cholesterol at a low dose as mentioned above, and also shows an excellent lowering effect on liver lipids. It has the advantage of having no side effects. The lipid-lowering agent of the present invention can be in any oral dosage form, such as soft capsules.
capsulae, hard capsules, granules, pills, pulveces, tabellae, syrupi, trochis, elixiria The following dosage forms can be exemplified. Means for preparing such dosage forms are well known to those skilled in the art and can be utilized in the present invention. The lipid lowering agent of the present invention has an intrinsic viscosity [η] of 0.29.
In addition to containing the partially degraded dextran of ~1.1 as an active ingredient, it can be in the form of a composition that further contains a pharmaceutically acceptable diluent or carrier. In such a form, the content of the active ingredient can be appropriately selected. The content can be suitably selected and changed depending on the dosage form, but for example, the content may be about 1 to about 99% by weight, preferably about 5 to about 95% by weight, based on the weight of the composition. I can do it. Examples of diluents or carriers utilized in such compositions include karaya gum, acacia, tragacanth, guar gum, carrageenin, sodium alginate, casein, gelatin, gluten, potato starch, wheat starch, corn starch, rice starch, and sweet potato. starch, agar,
Shellac, glucomannan, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyethylene glycol, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, carboxymethylstarch, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, carbonic acid Sodium hydrogen, magnesium oxide, calcium lactate, calcium carbonate, calcium phosphate, synthetic aluminum silicate, magnesium stearate, magnesium aluminate metasilicate, silicic acid, talc, boric acid, calcium sulfate, benzoic acid, citric acid, succinic acid, tartaric acid , gluconic acid, glycerin, sucrose, mannitol,
Examples include glucose, sorbitol, lactose, fructose, saccharin, water, and ethanol. The lipid-lowering agent of the present invention can be orally administered in the above-mentioned amount to humans who have or are at risk of hyperlipidemia. Hyperlipidemia can be primary, familial or idiopathic, such as arteriosclerosis (ischemic heart disease, myocardial infarction), cerebral arteriosclerosis (cerebral infarction, cerebral thrombosis), and hyperlipidemia. It may be a cause of liver disease, or it may be secondary hyperlipidemia induced by obesity, diabetes, abnormal glucose metabolism, hyperinsulinemia, etc. Furthermore, the partially degraded dextran of the present invention can be administered to the above-mentioned diseases that may induce secondary hyperlipidemia and to humans (including healthy individuals) who may be at risk of hyperlipidemia. It can also be administered. Next, the lipid-lowering effect of dextran will be described. Test Example 1 Male Wistar rats weighing around 105 g were fed ad libitum with a high sucrose diet (high sucrose diet vs. dextran = 500:1) containing dextran with an intrinsic viscosity [η] of 0.11 to 1.72. Let me,
After rearing for 14 days, serum triglyceride (TG), serum total cholesterol (TC), and blood sugar were determined by standard methods. The results are shown in Table 1.
ãè¡šã
第ïŒè¡šã«ç€ºãããšããããã¹ãã©ã³é
åé«ã·ãš
ç³é£ãäžããè©ŠéšçŸ€ã§ã¯ãããã¹ãã©ã³æªé
åã®
é«ã·ãšç³é£ãäžãã察ç
§çŸ€ã«æ¯ã¹ãTGåã³TC
ã®å¢å æå¶ãã¿ããããç¹ã«æ¥µéç²åºŠãηãã
0.30ã1.06ã®ããã¹ãã©ã³ãé
åãã矀ã§ã¯TG
åã³TCã®å¢å ãææã«æå¶ããããäžæ¹ãè¡ç³
ã«å¯Ÿãã圱é¿ã¯å
šãã¿ãããªãã€ãã
è©ŠéšäŸ ïŒ
äœé105gååŸã®ãŠã€ã¹ã¿ãŒïŒWistarïŒç³»éæ§
ã©ããã«ã極éç²åºŠãηãã0.63ã®ããã¹ãã©ã³
ãçš®ã
ã®å²åã§ããããé
åããé«ã·ãšç³é£ãèª
ç±æåãããŠã14æ¥é飌è²ããåŸãTGãTCå
ã³èè質ãå®éãããçµæã第ïŒè¡šã«ç€ºãã
ãªããèè質ã¯è湿ééã«å¯Ÿã30åéã®ã¢ã»ã
ã³ãå ããã¢ãžããŒããããã®é å¿äžæž
ãèžçºä¹Ÿ
åºããŠããã®ééã秀ãããšã«ããæ±ããã[Table] As shown in Table 1, the test group fed a high-sucrose diet containing dextran had higher TG and TC compared to the control group fed a high-sucrose diet without dextran.
The increase was suppressed. In particular, the intrinsic viscosity [η]
TG in the group containing 0.30-1.06 dextran
and the increase in TC was significantly suppressed. On the other hand, no effect on blood sugar was observed. Test Example 2 Male Wistar rats weighing around 105 g were fed ad libitum with a high sucrose diet containing various proportions of dextran with an intrinsic viscosity [η] of 0.63, and after being reared for 14 days, TG , TC and hepatic lipids were quantified. The results are shown in Table 2. The liver lipids were determined by adding 30 times the amount of acetone to the liver wet weight and homogenizing the liver, evaporating the centrifuged supernatant to dryness, and weighing it.
ãè¡šã
第ïŒè¡šã«ç€ºãåŠããé«ã·ãšç³é£ïŒKgã«å¯Ÿãã極
éç²åºŠãηãã0.63ã®ããã¹ãã©ã³ã0.5ã5gé
åãã飌æãäžããåè©ŠéšçŸ€ã§ã¯ãããã¹ãã©ã³
æªé
åã®é«ã·ãšç³é£ãäžãã察ç
§çŸ€ã«æ¯ã¹ã
TGïŒTCåã³èè質ã®å¢å ãææã«æå¶ãããã
ãªããè©ŠéšäŸïŒåã³ïŒã«ãããŠçšããé«ã·ãšç³
é£ã®çµæã¯æ¬¡ã®éãã§ããã
é«ã·ãšç³é£ã®çµæ
ã·ãšç³ 69.9ïŒ
ã«ãŒã€ã³ 25ïŒ
æ··åãã¿ãã³ïŒãã³ãã¿ã³æ«ïŒ 0.85ïŒ
æ··åå¡©ïŒããŒããŒå¡©ïŒ ïŒïŒ
å¡©åã³ãªã³ 0.15ïŒ
ã³ãŒã³æ²¹ 0.1ïŒ
è©ŠéšäŸ ïŒ
äœé110gååŸã®ãŠã€ã¹ã¿ãŒïŒWistarïŒç³»éæ§
ã©ããã«ã極éç²åºŠãηãã0.53ã®ããã¹ãã©ã³
ãé
åããé«èèªé£ïŒé«èèªé£å¯Ÿããã¹ãã©ã³ïŒ
500察ïŒïŒãèªç±æåãããŠã14æ¥é飌è²ããåŸã
åžžæ³ã«ããTGåã³TCãå®éãããçµæã第ïŒ
è¡šã«ç€ºãã[Table] As shown in Table 2, in each test group fed feed containing 0.5 to 5 g of dextran with an intrinsic viscosity [η] of 0.63 per 1 kg of high sucrose diet, the high sucrose diet without dextran Compared to the control group given
Increases in TG, TC, and hepatic lipids were significantly suppressed. The composition of the high sucrose diet used in Test Examples 1 and 2 is as follows. Composition of high sucrose diet Sucrose 69.9% Casein 25% Mixed vitamins (Panvitan powder) 0.85% Mixed salt (Harper's salt) 4% Choline chloride 0.15% Corn oil 0.1% Test example 3 Wistar male weighing around 110g Rats were fed a high-fat diet containing dextran with an intrinsic viscosity [η] of 0.53 (high-fat diet vs. dextran =
After breeding for 14 days with ad libitum intake of 500:1),
TG and TC were quantified by conventional methods. 3rd result
Shown in the table.
ãè¡šã
第ïŒè¡šã«ç€ºãåŠãã極éç²åºŠãηãã0.53ã®ã
ãã¹ãã©ã³ãé
åããé«èèªé£ãäžããè©ŠéšçŸ€ã§
ã¯ãããã¹ãã©ã³æªé
åã®é«èèªé£ãäžãã察ç
§
矀ã«æ¯ã¹TGåã³TCã®å¢å ãææã«æå¶ãããã
ãªããè©ŠéšäŸïŒã«ãããŠçšããé«èèªé£ã®çµæ
ã¯æ¬¡ã®éãã§ããã
é«èèªé£ã®çµæ
ã·ãšç³ 61ïŒ
ã«ãŒã€ã³ 22ïŒ
æ··åãã¿ãã³ïŒãã³ãã¿ã³æ«ïŒ 0.85ïŒ
æ··åå¡©ïŒããŒããŒå¡©ïŒ 4.0ïŒ
å¡©åã³ãªã³ 0.15ïŒ
ã³ãŒã³æ²¹ 1.0ïŒ
ã³ã¬ã¹ãããŒã« 1.0ïŒ
ã©ãŒã 10ïŒ
å®æœäŸ ïŒ
äžèšçµæã®é å€ïŒ400mgïŒé ïŒããéåžžã®æ¹æ³
ã§è£œé ããã
ããã¹ãã©ã³ïŒãηãïŒ0.53ïŒ 25ïŒ
ã·ãšç³ 25ïŒ
ä¹³ç³ 48.5ïŒ
ããããã·ãããã«ã»ã«ããŒã¹ 0.5ïŒ
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã ïŒïŒ
å®æœäŸ ïŒ
äžèšçµæã®æåãæ··åããNo.ïŒã®ãŒã©ãã³ã«ã
ã»ã«ã«å
å¡«ããŠãã«ãã»ã«å€ïŒ200mgïŒã«ãã»ã«ïŒ
ãšããã
ããã¹ãã©ã³ïŒãηãïŒ0.63ïŒ 80ïŒ
ãªã³é
žæ°ŽçŽ ã«ã«ã·ãŠã 19ïŒ
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã ïŒïŒ
å®æœäŸ ïŒ
äžèšçµæã®é¡ç²å€ããéåžžã®æ¹æ³ã§è£œé ããã
ããã¹ãã©ã³ïŒãηãïŒ0.75ïŒ 50ïŒ
ä¹³ç³ 48ïŒ
ããããã·ãããã«ã»ã«ããŒã¹ ïŒïŒ
å®æœäŸ ïŒ
äžèšçµæã®é å€ïŒ250mgïŒé ïŒããéåžžã®æ¹æ³
ã§ç³è¡£é ãšããã
ããã¹ãã©ã³ïŒãηãïŒ0.80ïŒ 40ïŒ
å°éºŠã§ãã·ã 4.5ïŒ
çµæ¶ã»ã«ããŒã¹ 10ïŒ
10ïŒ
ãã¬ã€ã·ãšã§ãã·ãç³ 45ïŒ
ã¿ã«ã¯ 0.5ïŒ
å®æœäŸ ïŒ
äžèšçµæã®æº¶æ¶²ãé©åœãªå®¹åšã«å泚ããŠæ»
èã
ãŠæ¶²å€ãšããã
ããã¹ãã©ã³ïŒãηãïŒ0.30ïŒ 15ïŒ
ã·ãšç³ ïŒïŒ
ã°ã«ã³ãŒã¹ ïŒïŒ
èžçæ°Ž 77ïŒ
å®æœäŸ ïŒ
äžèšçµæã®ãããŒãå€ïŒ1gïŒé ïŒããéåžžã®
æ¹æ³ã§è£œé ããã
ããã¹ãã©ã³ïŒãηãïŒ1.06ïŒ 15ïŒ
氎风 25ïŒ
ã·ãšç³ 57ïŒ
ã¢ã©ãã¢ãŽã æ« ïŒïŒ
èžçæ°Ž é© é
å®æœäŸ ïŒ
äžèšçµæã®æ£å€ãéåžžã®æ¹æ³ã§è£œé ããã
ããã¹ãã©ã³ïŒãηãïŒ0.41ïŒ 70ïŒ
ããŠã¢ãã³ã·ã§ãã·ã 19ïŒ
ä¹³ç³ 20ïŒ
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã ïŒïŒ
å®æœäŸ ïŒ
ããã¹ãã©ã³ïŒãηãïŒ0.53ïŒããNo.ïŒã®ãŒã©ã
ã³ã«ãã»ã«ã«200mgãã€å
å¡«ããŠãã«ãã»ã«å€ãš
ããã
èšåºäŸ ïŒ
é«ããªã°ãªã»ã©ã€ãè¡çæ£è
10åã«å¯Ÿããã«ã
ã»ã«ã«å
å¡«ããããã¹ãã©ã³ïŒãηãïŒ0.53ïŒãæ¯
é£åãïŒæ¥ïŒåãïŒé±éæçšããããããã¹ãã©
ã³æçšååŸã®TGã¯ç¬¬ïŒè¡šã®éãã§ãã€ãã[Table] As shown in Table 3, the test group fed a high-fat diet containing dextran with an intrinsic viscosity [η] of 0.53 had lower TG and TC levels compared to the control group fed a high-fat diet containing no dextran. The increase was significantly suppressed. The composition of the high-fat food used in Test Example 3 is as follows. Composition of high-fat diet Sugar 61% Casein 22% Mixed vitamins (Panvitan powder) 0.85% Mixed salt (Harper's salt) 4.0% Choline chloride 0.15% Corn oil 1.0% Cholesterol 1.0% Lard 10% Example 1 Tablets with the following composition ( 400 mg/tablet) was prepared in a conventional manner. Dextran ([η] = 0.53) 25% Cane sugar 25% Lactose 48.5% Hydroxypropyl cellulose 0.5% Magnesium stearate 1% Example 2 Mix the ingredients with the following composition, fill it into No. 1 gelatin capsule, and make a capsule. Agent (200mg/capsule)
And so. Dextran ([η]=0.63) 80% Calcium hydrogen phosphate 19% Magnesium stearate 1% Example 3 Granules having the following composition were produced by a conventional method. Dextran ([η]=0.75) 50% Lactose 48% Hydroxypropylcellulose 2% Example 4 Tablets (250 mg/tablet) having the following composition were made into sugar-coated tablets by a conventional method. Dextran ([η] = 0.80) 40% Wheat starch 4.5% Crystalline cellulose 10% 10% potato starch paste 45% Talc 0.5% Example 5 A solution with the following composition was dispensed into a suitable container and sterilized to form a liquid. . Dextran ([η]=0.30) 15% Cane sugar 3% Glucose 5% Distilled water 77% Example 6 A lozenge (1 g/tablet) having the following composition was produced by a conventional method. Dextran ([η]=1.06) 15% Starch syrup 25% Cane sugar 57% Gum arabic powder 3% Distilled water Appropriate amount Example 7 A powder having the following composition was produced by a conventional method. Dextran ([η] = 0.41) 70% Corn starch 19% Lactose 20% Magnesium stearate 1% Example 8 Dextran ([η] = 0.53) was filled into No. 1 gelatin capsules at 200 mg each to form capsules. And so. Clinical Example 1 Ten patients with hypertriglyceridemia were given dextran ([η] = 0.53) filled in capsules before each meal, three times a day for 4 weeks. TG before and after taking dextran was as shown in Table 4.
ãè¡šã
第ïŒè¡šã«ç€ºãåŠãã10åã®é«ããªã°ãªã»ã©ã€ã
è¡çæ£è
ã«å¯Ÿãã極éç²åºŠãηãã0.53ã®ããã¹
ãã©ã³ãïŒã50mgïŒKgâäœéïŒæ¥æçšããããšã
ããïŒã50mgïŒKgâäœéïŒæ¥æçšãããæ£è
ã®
TGã¯äœäžããç¹ã«ïŒã30mgïŒKgâäœéïŒæ¥æçš
ãããæ£è
ã§ã¯å€§å·Ÿã«äœäžããã
ãŸããïŒã30mgïŒKgâäœéïŒæ¥æçšæ£è
ã§ã¯ã
ãã¹ãã©ã³æçšã«ããå¯äœçšã¯å
šãèªããããªã
ã€ããã50mgïŒKgã»äœéïŒæ¥æçšæ£è
ã§ã¯è»äŸ¿åŸ
åãèªãããã®ããã€ãã[Table] As shown in Table 4, when dextran with an intrinsic viscosity [η] of 0.53 was administered to 10 patients with hypertriglyceridemia at 2 to 50 mg/Kg - body weight/day, the results were 4 to 50 mg/Kg. - body weight/day of patients taken
TG decreased, particularly in patients taking 4-30 mg/Kg body weight/day. Furthermore, in patients taking 2 to 30 mg/Kg body weight/day, no side effects were observed due to taking dextran, but in some patients taking 50 mg/Kg body weight/day, a tendency towards loose stools was observed.
Claims (1)
ã¹ãã©ã³ãæå¹æåãšããŠå«æããããšãç¹åŸŽãš
ããè質äœäžå€ã ïŒ æ¥µéç²åºŠïŒ»Î·ïŒœã0.29ã1.1ã®éšåå解ãã
ã¹ãã©ã³ãšè¬åŠçã«èš±å®¹ãåŸãçšéå€ä¹è³æ äœã
ããªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®è質äœäžå€ã[Scope of Claims] 1. A lipid-lowering agent characterized by containing partially decomposed dextran having an intrinsic viscosity [η] of 0.29 to 1.1 as an active ingredient. 2. The lipid-lowering agent according to claim 1, comprising a partially decomposed dextran having an intrinsic viscosity [η] of 0.29 to 1.1 and a pharmaceutically acceptable diluent or carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4490284A JPS60190717A (en) | 1984-03-09 | 1984-03-09 | Agent and method for reducing lipid level |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4490284A JPS60190717A (en) | 1984-03-09 | 1984-03-09 | Agent and method for reducing lipid level |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60190717A JPS60190717A (en) | 1985-09-28 |
JPH052652B2 true JPH052652B2 (en) | 1993-01-13 |
Family
ID=12704398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4490284A Granted JPS60190717A (en) | 1984-03-09 | 1984-03-09 | Agent and method for reducing lipid level |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60190717A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118449A (en) * | 1991-05-13 | 1992-06-02 | Glitsch, Inc. | Method of and apparatus for cartridge tray sealing |
EP1060673B1 (en) * | 1999-05-20 | 2004-07-14 | Société des Produits Nestlé S.A. | Method for increasing the production of propionate in the gastro-intestinal tract |
NL1013175C2 (en) * | 1999-09-29 | 2001-03-30 | Nutricia Nv | Food compositions containing non-digestible polysaccharides and use thereof for reducing transport through tight junctions. |
-
1984
- 1984-03-09 JP JP4490284A patent/JPS60190717A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS60190717A (en) | 1985-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cézard et al. | Efficacy and tolerability of racecadotril in acute diarrhea in children | |
TW518222B (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
US8679549B2 (en) | Electrolyte purgative | |
US4965252A (en) | Cholesterol-lowering combination compositions of guar gum and niacin | |
JP2016065069A (en) | Prebiotic formulations and methods of use | |
US8017652B2 (en) | Activators of peroxisome proliferator-activated receptors | |
WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
JP2014037422A (en) | Use of water-soluble cellulose derivative for prevention or treatment of metabolic syndrome | |
FR2904774A1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A REGULATOR AGENT FOR INTESTINAL MOTILITY AND AN ANTIFLATULENT. | |
AU2012203730B2 (en) | Composition and method for preventing or reducing the risk of developing a syndrome | |
JP3055948B2 (en) | Agent for improving skin pruritus associated with renal failure | |
US6509035B1 (en) | Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same | |
JPH052652B2 (en) | ||
JPS6299323A (en) | Agent for hyperlipemia | |
KR20060037408A (en) | Carbostyril derivatives for accelerating salivation | |
JP3455633B2 (en) | Agent for preventing or treating ulcerative colitis | |
CA2062091C (en) | Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers | |
JPS6210013A (en) | Remedy and preventive for gastritis | |
JPS60120812A (en) | Remedy for diabetic osteopenia | |
JPH05294837A (en) | Sebum-secretion promoting agent | |
JPS59175425A (en) | Vessel strengthening agent | |
JPS6260369B2 (en) | ||
JP3035328B2 (en) | Blood lipid lowering agent | |
EP2288342A1 (en) | Magnesium system and use thereof in the cosmetics industry | |
JP3889456B2 (en) | Glycerophosphate dehydrogenase inhibitor |